Navigation Links
Penn researchers discover new target for preventing and treating flu
Date:1/30/2008

PHILADELPHIA - Emerging subtypes of influenza A virus hold the potential to initiate a world-wide epidemic in the next few years, according to World Health Organization officials. However, almost all type A influenza viral strains have become resistant to amantadine and rimantadine, two drugs that make up one of only two classes used to treat the flu.

Researchers at the University of Pennsylvania School of Medicine have now provided a new strategy for designing drugs that target the resistant viral strains by solving the three-dimensional structure of a viral protein called the M2 proton channel. This protein is the molecular receptor for these drugs. This study is published in the Jan. 31 issue of the journal Nature.

The M2 protein is located in the viral envelope, forming a long, narrow channel that allows the flow of protons into the viral interior, an essential step for infection. Amantadine sits in this channel and blocks the flow of protons, thus halting infection. In non-resistant viruses, amantadine acts like a cork lodged deep in the channel.

We know that resistance to amantadine is caused by a mutation in the virus M2 protein, but we did not know how this mutation caused resistance, explains senior author William F. DeGrado, PhD, Professor of Biochemistry and Biophysics. Now we do the mutation changes the shape of the channel so amantadine can no longer do its job."

The structure revealed that there is a pocket in the channel next to the location where amantadine fits that is conserved in all influenza A viruses. This newly discovered space could be the target for new drugs. "Inhibitors that target this cavity adjacent to two highly conserved amino acids in M2 might reclaim the M2-blocking class of drugs so that ongoing endemic outbreaks and future pandemics of this deadly virus might be prevented and treated," says DeGrado.

"The crystal structures of influenza M2 with and without the anti-influen
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

1

GOOD

Page: 1 2

Related medicine news :

1. Researchers investigate links between prostate, cadmium, zinc
2. New nanotube findings by Stanford researchers give boost to potential biomedical applications
3. Researchers Map Paths Governing Neuron Function
4. Cold Spring Harbor Laboratory researchers race against time to save Tasmanian devils
5. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
6. Pain medicine meeting unites top researchers and clinicians
7. Researchers identify brains eureka circuitry
8. Researchers find relief for chronic pain
9. Researchers propose consumers buy yearly drug licenses as new way to pay for prescriptions
10. Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
11. DOE awards supercomputing time to UCSD, SDSC researchers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn researchers discover new target for preventing and treating flu
Penn researchers discover new target for preventing and treating flu
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
....1 lakh chickens in 354 villages in Jalgaon distri...d people that there was no cause for panic.// Dist...s had been identified as being within a radius of ...Animal Diseases Laboratory in Bhopal. This third ...
...some people may be due to their inability of the b... disorder (ASD), it is characterised by varying de...l interaction and restricted, repetitive and stere...ur. It had been thought that lack of social skill...
... to the fumes of solvents used in house renovation...and lacquers//, could give rise to allergies in yo...al medical specialist at Germany's environmental a...novation work to their husbands or hired professio...
... people in North Shropshire and Wales and funded b...r// drug Herceptin, free to the Welsh breast cance... at ?47,000, will have to be borne by the other ca... With effect from February, all Welsh local Healt...
Other Medicine News:
(Date:10/7/2008)...al abstracts highlighting CIMZIA,s long-term benef...e patients presented at American College,of Gastro...e-FirstCall/ -- Data from two studies,presented th...terology,(ACG) Annual Meeting demonstrate that CIM...nti-TNF alpha (Tumor Necrosis Factor alpha) - prov...
(Date:10/7/2008)...d 15 Patient Cohort Enrolled in Stage A of Trial A...With Carboplatin and Paclitaxel -, TUSTIN, Calif....aceuticals, Inc. (Nasdaq: PPHM ), a clinical stag...antibodies for the treatment of cancer and,hepatit...t has completed,enrollment in the first stage of a...
(Date:10/6/2008)... and CHIPPENHAM, England, October 7 /PRNewswire-Fi...Mothers Index: 4565) and Vectura,Group plc ("Vectu...tudies,evaluating the efficacy, safety and tolerab...f the European Respiratory Society (ERS) in Berlin...ronium bromide), a novel,inhaled long-acting musca...
(Date:10/6/2008)...N, Oct. 6 /PRNewswire-USNewswire/ -- "A return to ...e development is without scientific,justification,...al,Alternatives to Laboratory Animals (ATLA). "An ...ine Research" concludes that vaccine responses in,...ans, and that claims of,chimpanzees, critical role...
Breaking Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Some Immature Brain Cells May Promote Tumors 9157 1Some Immature Brain Cells May Promote Tumors 9157 2Start Your Day the Sun Shower 28TM 29 Way 9152 1Start Your Day the Sun Shower 28TM 29 Way 9152 2Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference 9147 1Kiwa Fertilizers Pass Independent Tests 2483 1Kiwa Fertilizers Pass Independent Tests 2483 2Kiwa Fertilizers Pass Independent Tests 2483 3
... MALVERN, Pa.--(BUSINESS WIRE)--Apr 18, 2007 - Gem...preclinical data,from a study of its lead compound...tic leukemia (ALL). The study was discussed in an,...rican Association,for Cancer Research (AACR). Acco...ingle agent activity against ALL blast cells,and ...
...lif. and LOS ANGELES, April 18, 2007,/PRNewswire-F...ata,from two preclinical studies, one identifying ...tylase (HDAC) inhibitor and,another demonstrating ...tyrosine kinase (BTK) inhibitor compounds. The dat...ancer Research (AACR),2007 Annual Meeting being he...
Other Medicine Technology:Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5
... of deflectable curve catheters designed to specif...r patients with small anatomies. Each catheter is ... the finest materials. A unique multi-step process...ion technologies results in the excellent torque a...
... of fixed curve catheters designed to specifically...ents with small anatomies. Each catheter is handcr...inest materials. A unique multi-step process that ...chnologies results in the excellent torque and fle...
4Fr, 5Fr & 6Fr diagnostic electrophysiology catheters with fixed curves.
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism.
Medicine Products: